CTLA4 and glioblastoma: C5AR1 predicted a worse therapy outcome of PD1+CTLA4 in melanoma and of PD1 in GBM and kidney cancer (Figure 6D). Finally, C3AR1 was associated with a better therapy outcome of PDI and CTLA4 in melanoma and a worse outcome of PD1 therapy in GBM cancer (Figure 6E).